Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1851 - Reporting of results of randomized trials in common cancers in the lay media


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Bioethical Principles and GCP


Domen Ribnikar


Annals of Oncology (2017) 28 (suppl_5): v511-v520. 10.1093/annonc/mdx385


D. Ribnikar1, H. Goldvaser2, A. Ocana Fernandez3, A. Templeton4, B. Seruga5, E. Amir2

Author affiliations

  • 1 Division Of Medical Oncology And Hematology, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 2 Division Of Medical Oncology And Hematology, Princess Margaret Cancer Center, Toronto/CA
  • 3 Research Unit, Albacete University Hospital, Albacete/ES
  • 4 Department Of Oncology, St. Claraspital Basel, Basel/CH
  • 5 Department Of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana/SI


Abstract 1851


Limited data exist about the role of the lay media (including the financial press) in the dissemination of results of randomized controlled trials (RCTs) in common cancers.


We searched clinicaltrials.gov to identify phase III RCTs evaluating new drugs in breast, colorectal, lung and prostate cancer. We included all completed and active trials that have completed accrual between 1 January 2005 and 31 October 2016. Reporting of trials in the lay media was identified by a systematic search of Lexis-Nexis Academic using the name of the drug and trial. Scientific reporting was defined as presentation at a conference or publication in full in the scientific literature. Associations between reporting in the lay media before scientific reporting and study design, results and sponsorship were evaluated using logistic regression.


Of the 180 RCTs identified, 55% were positive, 79% were performed with palliative intent and 79% evaluated targeted therapies (including endocrine and immunotherapy). We identified 93 (52%) reports in the lay media (66% of positive trials and 38% of negative trials). In 49 cases (27%) reporting in the lay media occurred before scientific reporting with an increasing trend over time (p = 0.009). Among these, 53% presented quantitative data. The median time between lay media reporting and scientific reporting was 16 weeks (range 1-220 weeks). Reporting in the lay media before scientific reporting was associated with positive results (OR 3.12, p 


Over a quarter of all RCTs in common cancers are reported in the lay media before they are reported scientifically. Positive trials, industry sponsorship, palliative intent, journal impact factor and evaluation of new targeted therapy, especially in prostate cancer are associated with early reporting in the lay media.

Clinical trial identification

Legal entity responsible for the study

Eitan Amir




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.